PD-1 tended to increase in TAMs isolated from VIP antagonist-treated mice, and therefore we hypothesized that the combined treatment of VIP antagonist and anti-PD-1 antibody may have an additional effect on reducing tumor growth and enhancing macrophage function. The gene discussed is VIP; the disease is neoplasm.